Diabetes drug no better than placebo for MACE, trial shows
AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.
A trial of ertugliflozin in patients with type 2 diabetes (T2DM) and established atherosclerotic CVD has found no difference in outcomes for major adverse cardiac events (MACE) between the drug and placebo, researchers report.
But the VERTIS CV trial does confirm earlier findings of a reduced risk of admission for heart failure in patients with T2DM taking the SGLT2 inhibitor, with results showing a 30% lower risk of this event in those on the drug.
The findings were announced at the European Society of Cardiology’s 2020 (ESC 2020) virtual congress this week.